Highlights
● XBB.1.5-containing bivalent generated superior immunogenicity against XBB lineages compared to BA.2/BA.5-containing bivalent.
● The efficacy of booster dose against XBB lineages waned after 2-3 months.
● Newer variant-matched vaccine elicits an enhanced immune response against newly emerged variants.